The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis.

Infect Drug Resist

Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Published: January 2022

AI Article Synopsis

  • GeneXpert MTB/RIF is a rapid diagnostic tool that aids in starting treatment for multidrug-resistant tuberculosis (MDR-TB) more quickly, and this study examines its impact in Ethiopia.
  • The study analyzed 465 MDR-TB patients and found that 46.7% were diagnosed using GeneXpert, with several factors linked to delays in treatment identified through statistical analysis.
  • Results indicated that using the GeneXpert test significantly reduced treatment delays by 41%, suggesting that expanding access to this technology could enhance the healthcare system and speed up MDR-TB treatment initiation.

Article Abstract

Background: GeneXpert MTB/RIF testing is a rapid molecular diagnostic test that is performed with an automated cartilage-based machine that makes treatment initiation prompt. This study aimed at evaluating the impact of GeneXpert in the reduction of treatment delay among multidrug-resistant tuberculosis (MDR-TB) patients in Amhara regional state of Ethiopia.

Methods: A facility-based retrospective follow-up study was conducted from January to February 2019, and a total of 465 MDR-TB patients were included in the study. Socio-demographic, clinical, and treatment-related characteristics were collected from patient's chart retrospectively using data abstraction sheets. Binary logistic regression model was fitted to identify factors associated with treatment delay; adjusted odds ratio (AOR) with a 95% confidence interval (CI) was computed to assess the strength of association. A propensity score-matched (PSM) analysis was used to assess the impact of the GeneXpert MTB/RIF test on treatment delay through calculation of average treatment effect (ATE).

Results: The majority, 92.4%, of patients had the pulmonary form of TB, and 46.7% of patients were diagnosed by GeneXpert MTB/RIF. The presence of cavitation (AOR = 0.62, 95% CI: 0.39 0.96), extrapulmonary form of TB (AOR = 0.34, 95% CI: 0.14 0.81), and GeneXpert (AOR = 0.15, 95% CI: 0.10 0.24) were factors associated with treatment delay. The average treatment effect (ATE) of PSM analysis showed that GeneXpert MTB/RIF has significantly reduced treatment delay by 41% compared to matched control groups.

Conclusion: This study revealed that GeneXpert test has a strong association with the reduced treatment delays among MDR-TB patients. This underscores that rapid molecular tests could help improve the health system and lead to prompt initiation of MDR-TB treatment. Therefore, expansion and decentralization of GeneXpert tests to peripheral health facilities are highly recommended. In turn, the case detection and control of the disease will be hastened.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803608PMC
http://dx.doi.org/10.2147/IDR.S345619DOI Listing

Publication Analysis

Top Keywords

treatment delay
24
genexpert mtb/rif
20
mdr-tb patients
12
treatment
11
genexpert
8
rapid molecular
8
impact genexpert
8
factors associated
8
associated treatment
8
psm analysis
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!